Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Menu

Rx Item-Terazosin 5Mg Cap 1000 By Jubilant Cadista Pharma Gen Hytrin

Terazosin 5Mg Cap 1000 By Jubilant Cadista Pharma Gen Hytrin Item No.: RX588071 NDC No.59746038510 59746-385-10 5974638510 UPC No.:359746385101 NDC No. 59746-0385-10 UPC/GTIN No. 3-59746-38510-1  3597Terazosin 5Mg Cap 1000 By Jubilant Cadista Pharma Gen Hytrin Item No.: RX588071 NDC No.59746038510 59746-385-10 5974638510 UPC No.:359746385101 NDC No. 59746-0385-10 UPC/GTIN No. 3-59746-38510-1  3597Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scopWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.NDC 59746-0385-10 UPC/GTIN No.3-59746-38510-1 Mfg.Part No.38510

Rx Item-Terazosin 5Mg Cap 1000 By Jubilant Cadista Pharma Gen Hytrin

$1556.84$139.99

Item No.: RX588071 NDC No.59746038510 59746-385-10 5974638510 UPC No.:359746385101 NDC No. 59746-0385-10 UPC/GTIN No. 3-59746-38510-1 359746385101 359746-385101 MPN 38510 Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,ResearchCo.,Uni.,VA,Vet & Wholesalers in scope of practice can order this RX Item. Rx Item No. Rx588071 Terazosin 5mg Cap 1000 by Jubilant Cadista Pharma Item No. 3588071 ND

Have a question?

Clinical Information
Gen. Code and Des.
22651 terazosin HCl ORAL CAPSULE 5 MG
GCN and Des.
47126 terazosin HCl ORAL CAPSULE 5 MG
Strength
5MG
Dose Form
CAPSULE
Product Category
RX Pharmaceuticals
Fine Line Class
850085008510 All Rx Products
DEA Class
NC
OMP Family

AHFS Class
24200000 ALPHA-ADRENERGIC BLOCKING AGENTS
24080400 ALPHA-ADRENERGIC BLOCKING AGT.(HYPOTEN)
24089200 HYPOTENSIVE AGENTS, MISCELLANEOUS
12160408 NON-SEL.ALPHA-1-ADRENERGIC BLOCKING AGTS
Active Ingredients
638 terazosin HCl 70024407
Inactive Ingredients
10141 red dye
10143 yellow dye
2432 lactose 64044515
2549 gelatin 9000708






TERAZOSIN HYDROCHLORIDE- terazosin hydrochloride capsule
Sandoz Inc
DESCRIPTION

Terazosin hydrochloride, an alpha-1-selective adrenoceptor blocking agent, is a quinazoline derivative represented by the following chemical name and structural formula: (RS)-Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-, monohydrochloride.
Terazosin hydrochloride is a white, crystalline substance, freely soluble in water and isotonic saline and has a molecular weight of 459.93. Terazosin capsules, USP, for oral administration, are supplied in four dosage strengths containing terazosin hydrochloride, USP equivalent to 1 mg, 2 mg, 5 mg, or 10 mg of terazosin. Inactive ingredients: Crospovidone, lactose (monohydrate), magnesium stearate, and microcrystalline cellulose. May contain corn starch. The capsule shells and imprinting inks contain: D & C Yellow #10 Aluminum Lake, FD & C Blue #1 Aluminum Lake, FD & C Blue #2 Aluminum Lake, FD & C Red #40 Aluminum Lake, gelatin, propylene glycol, shellac, synthetic black iron oxide, and titanium dioxide. The 5 mg also contains: D & C Red #28.
CLINICAL PHARMACOLOGY
Pharmacodynamics
A. Benign Prostatic Hyperplasia (BPH)

The symptoms associated with BPH are related to bladder outlet obstruction, which is comprised of two underlying components: a static component and a dynamic component. The static component is a consequence of an increase in prostate size. Over time, the prostate will continue to enlarge. However, clinical studies have demonstrated that the size of the prostate does not correlate with the severity of BPH symptoms or the degree of urinary obstruction. The dynamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck, leading to constriction of the bladder outlet. Smooth muscle tone is mediated by sympathetic nervous stimulation of alpha-1 adrenoceptors, which are abundant in the prostate, prostatic capsule and bladder neck. The reduction in symptoms and improvement in urine flow rates following administration of terazosin is related to relaxation of smooth muscle produced by blockade of alpha-1 adrenoceptors in the bladder neck and prostate. Because there are relatively few alpha-1 adrenoceptors in the bladder body, terazosin is able to reduce the bladder outlet obstruction without affecting bladder contractility.
INDICATIONS AND USAGE

Terazosin capsules, USP are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules, USP. The long-term effects of terazosin capsules, USP on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined.

Terazosin capsules, USP are also indicated for the treatment of hypertension. Terazosin capsules, USP can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.
CONTRAINDICATIONS

Terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.
WARNINGS
Syncope and "First-dose" Effect

Terazosin capsules, like other alpha-adrenergic blocking agents, can cause marked lowering of blood pressure, especially postural hypotension, and syncope in association with the first dose or first few days of therapy. A similar effect can be anticipated if therapy is interrupted for several days and then restarted. Syncope has also been reported with other alpha-adrenergic blocking agents in association with rapid dosage increases or the introduction of another antihypertensive drug. Syncope is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by a bout of severe supraventricular tachycardia with heart rates of 120 to 160 beats per minute. Additionally, the possibility of the contribution of hemodilution to the symptoms of postural hypotension should be considered.
DOSAGE AND ADMINISTRATION

If terazosin capsules administration is discontinued for several days, therapy should be reinstituted using the initial dosing regimen.
Benign Prostatic Hyperplasia
Initial Dose

1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded as an initial dose. Patients should be closely followed during initial administration in order to minimize the risk of severe hypotensive response.
Subsequent Doses

The dose should be increased in a stepwise fashion to 2 mg, 5 mg, or 10 mg once daily to achieve the desired improvement of symptoms and/or flow rates. Doses of 10 mg once daily are generally required for the clinical response. Therefore, treatment with 10 mg for a minimum of 4 to 6 weeks may be required to assess whether a beneficial response has been achieved. Some patients may not achieve a clinical response despite appropriate titration. Although some additional patients responded at a 20 mg daily dose, there was an insufficient number of patients studied to draw definitive conclusions about this dose. There are insufficient data to support the use of higher doses for those patients who show inadequate or no response to 20 mg daily. If terazosin administration is discontinued for several days or longer, therapy should be reinstituted using the initial dosing regimen.
Hypertension

The dose of terazosin capsules and the dose interval (12 or 24 hours) should be adjusted according to the patient's individual blood pressure response. The following is a guide to its administration:
Initial Dose

1 mg at bedtime is the starting dose for all patients, and this dose should not be exceeded. This initial dosing regimen should be strictly observed to minimize the potential for severe hypotensive effects.
Subsequent Doses

The dose may be slowly increased to achieve the desired blood pressure response. The usual recommended dose range is 1 mg to 5 mg administered once a day; however, some patients may benefit from doses as high as 20 mg per day. Doses over 20 mg do not appear to provide further blood pressure effect and doses over 40 mg have not been studied. Blood pressure should be monitored at the end of the dosing interval to be sure control is maintained throughout the interval. It may also be helpful to measure blood pressure 2 to 3 hours after dosing to see if the maximum and minimum responses are similar, and to evaluate symptoms such as dizziness or palpitations which can result from excessive hypotensive response. If response is substantially diminished at 24 hours an increased dose or use of a twice daily regimen can be considered. If terazosin administration is discontinued for several days or longer, therapy should be reinstituted using the initial dosing regimen. In clinical trials, except for the initial dose, the dose was given in the morning.

Terazosin 5Mg Cap 1000 By Jubilant Cadista Pharma Gen Hytrin Item No.: RX588071 NDC No.59746038510 59746-385-10 5974638510 UPC No.:359746385101 NDC No. 59746-0385-10 UPC/GTIN No. 3-59746-38510-1  3597
Terazosin 5Mg Cap 1000 By Jubi
Terazosin 5Mg Cap 1000 By Jubilant Cadista Pharma Gen Hytrin Item No.: RX588071 NDC No.59746038510 59746-385-10 5974638510 UPC No.:359746385101 NDC No. 59746-0385-10 UPC/GTIN No. 3-59746-38510-1 3597

Terazosin 5Mg Cap 1000 By Jubilant Cadista Pharma Gen Hytrin Item No.: RX588071 NDC No.59746038510 59746-385-10 5974638510 UPC No.:359746385101 NDC No. 59746-0385-10 UPC/GTIN No. 3-59746-38510-1  3597
Terazosin 5Mg Cap 1000 By Jubilant Cadis
Terazosin 5Mg Cap 1000 By Jubilant Cadista Pharma Gen Hytrin Item No.: RX588071 NDC No.59746038510 59746-385-10 5974638510 UPC No.:359746385101 NDC No. 59746-0385-10 UPC/GTIN No. 3-59746-38510-1 3597

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
Click above for all TERAZOSIN
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

NDC 59746-0385-10 UPC/GTIN No.3-59746-38510-1 Mfg.Part No.38510
RX ITEM-Terazosin 5Mg Cap 1000 By Jubila
NDC 59746-0385-10 UPC/GTIN No.3-59746-38510-1 Mfg.Part No.38510